Brief: Crescita Therapeutics says signed a license agreement with a U.S.-based dermatological contract research company
21/03/2017 11:30
March 21 (Reuters) - Crescita Therapeutics Inc CTX.TO
* Crescita Therapeutics Inc - signed an exclusive license
agreement with a U.S.-based, major dermatological contract
research company
* Crescita Therapeutics Inc says licensee will be
responsible for developing up to three dermatological products
* Crescita Therapeutics Inc - licensee will oversee and fund
cost of all development activities until commercialization
partner for products are secured
* Crescita Therapeutics Inc - Crescita is entitled to a
share of royalties and other consideration received by licensee
from partners
Source text for Eikon: urn:newsml:reuters.com:*:nPn9fH42Xa
Further company coverage: CTX.TO
((bangalore.newsroom@thomsonreuters.com;))
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium